Context Therapeutics (CNTX) AI Stock Analysis

• Market Cap: $69.98M
• Dividend Yield: N/A
• Average Volume (3M): 189.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: N/A
• EPS Growth: 65.02%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 89,704,190
• 10 Day Avg. Volume: 421,933
• 30 Day Avg. Volume: 189,349
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 11.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.50
• Price Target Upside: 476.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Context Therapeutics is facing substantial financial difficulties with no revenue and persistent losses. While technical analysis indicates a bearish trend and valuation metrics demonstrate overvaluation, recent corporate events offer some potential for future growth. However, the company’s financial instability and lack of profitability heavily weigh down its overall stock attractiveness.

Positive Factors

Clinical Development

CTIM-76 has shown encouraging antitumor activity in preclinical studies, therefore, analysts continue to be optimistic about its potential differentiation from other CLDN6 targeted agents in development.

Financial Strength

CNTX raised $100M in a private placement, resulting in a year-end cash balance of $94.4M, which is expected to support operations into 2027.

Negative Factors

Market Conditions

Broad market headwinds continue in 2025 including continued challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.

Valuation Concerns

Valuations across much of the biotech space have continued to pullback and reset, for Context too, leading to an increased discount rate in the valuation model.

Context Therapeutics Business Overview & Revenue Model

Company Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Context Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company engages in strategic partnerships and collaborations with other pharmaceutical firms to advance its clinical trials and bring its therapies to market. Revenue is generated through milestone payments, licensing agreements, and potential future sales of approved drugs. Additionally, Context Therapeutics may receive funding through government grants and private investments to support its research and development activities.

Context Therapeutics Financial Statement Overview

Summary

Context Therapeutics faces severe financial challenges with no revenue generation and persistent losses. The balance sheet shows some improvement with increased equity, but the company remains reliant on external financing to bridge operational cash deficits. The financial health of the company is concerning given the industry dynamics and lack of profitability.

Income Statement

The income statement reveals significant challenges with no revenue generation and consistently negative net income, EBIT, and EBITDA over the years. The company is struggling with profitability and growth, reflected in the absence of gross profit and net profit margins.

Balance Sheet

The balance sheet shows an improvement in stockholders' equity and a reduction in liabilities over the years. However, the absence of revenue and high levels of net debt in past years highlight potential solvency issues. The debt-to-equity ratio has improved but remains a concern for financial stability.

Cash Flow

The cash flow statement indicates substantial negative free cash flow and operating cash flow, suggesting insufficient cash generation from operations. Although there is a recent influx of financing cash flow, the company heavily depends on external financing, posing risks to cash flow sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-12.04K	-9.27K	0.00	0.00
	EBIT
-29.92M	-25.07M	-15.38M	-10.53M	-2.57M
	EBITDA
-29.92M	-25.06M	-14.83M	-10.53M	0.00
	Net Income Common Stockholders
-26.73M	-23.96M	-14.29M	-7.43M	6.64M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
94.43M	14.45M	35.50M	49.64M	341.04K
	Total Assets
98.13M	16.06M	37.97M	51.31M	467.34K
	Total Debt
219.38K	0.00	55.08K	0.00	5.95M
	Net Debt
-94.21M	-14.45M	-35.44M	-49.64M	5.61M
	Total Liabilities
2.86M	4.19M	3.21M	3.03M	17.39M
	Stockholders Equity
95.27M	11.87M	34.76M	48.27M	-16.92M
Cash Flow		Free Cash Flow
-29.31M	-21.05M	-14.09M	-9.05M	-1.03M
	Operating Cash Flow
-14.56M	-21.05M	-13.55M	-8.80M	-1.03M
	Investing Cash Flow
-14.76M	0.00	-536.84K	-250.00K	0.00
	Financing Cash Flow
109.29M	0.00	-102.07K	58.39M	1.15M

Context Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.78
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Positive. The current price of 0.78 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.78, and below the 200-day MA of 1.58, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 32.74 is Neutral, neither overbought nor oversold. The STOCH value of 1.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTX.

Context Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMP	50 Neutral	$220.32M	―	-31.16%	―	―	15.17%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
MEIP	41 Neutral	$12.53M	―	-93.69%	―	-100.00%	-292.59%
KPTI	36 Underperform	$36.10M	―	41.08%	―	-0.55%	49.85%
IMUX	36 Underperform	$86.25M	―	-424.44%	―	―	51.02%
CARA	29 Underperform	$22.25M	―	-270.01%	―	-65.96%	40.80%
CNTX	28 Underperform	$69.98M	―	-49.89%	―	―	65.02%

Context Therapeutics Corporate Events

Context Therapeutics Begins Phase 1 Trial for CT-95

On April 9, 2025, Context Therapeutics announced the dosing of the first patient in its Phase 1 clinical trial for CT-95, a mesothelin x CD3 T cell engaging bispecific antibody. This marks Context’s second active clinical trial in 2025, following CTIM-76, and signifies progress in their mission to develop precision immunotherapies for solid tumors. The trial aims to evaluate the safety and efficacy of CT-95 in patients with mesothelin-expressing advanced solid tumors, with initial data expected in mid-2026.

Spark’s Take on CNTX Stock

According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.

Context Therapeutics faces significant financial challenges with no revenue generation and persistent losses, weighing heavily on its stock score. The technical analysis shows a bearish trend, and valuation metrics indicate unprofitability. However, positive corporate events, such as advancements in their clinical pipeline and leadership changes, offer some potential for future growth. Overall, the company’s financial instability and current market position limit its stock attractiveness.

To see Spark’s full report on CNTX stock, click here.

Context Therapeutics Advances CTIM-76 in Clinical Pipeline

On January 14, 2025, Context Therapeutics announced that the first patient has been dosed in their Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody. This trial marks a significant milestone in their clinical pipeline, targeting CLDN6-positive gynecologic and testicular cancers. The study aims to enroll up to 70 patients to assess safety, tolerability, and efficacy, with initial data expected in the first half of 2026. This development underscores Context’s potential impact on the treatment of CLDN6-positive cancers and further strengthens its position in the biopharmaceutical industry.

Context Therapeutics Appoints Andy Pasternak as Chairman

Context Therapeutics announced the appointment of Andy Pasternak as Chairman of its Board of Directors following the resignation of Richard Berman. Pasternak, with extensive experience in the pharmaceutical industry, is expected to lead the company into its next phase of growth, leveraging his background to advance Context’s work in the evolving field of T cell engagers.